<!DOCTYPE html>
<html class="client-nojs" lang="en" dir="ltr">
<head>
<meta charset="UTF-8"/>
<title>Management of Glaucoma in Eyes with Boston Keratoprosthesis - EyeWiki</title>
<script>document.documentElement.className="client-js";RLCONF={"wgBreakFrames":!1,"wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"mdy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgRequestId":"ZAVjVyqtces5pSwqKxE0kQAAABM","wgCSPNonce":!1,"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":!1,"wgNamespaceNumber":0,"wgPageName":"Management_of_Glaucoma_in_Eyes_with_Boston_Keratoprosthesis","wgTitle":"Management of Glaucoma in Eyes with Boston Keratoprosthesis","wgCurRevisionId":84960,"wgRevisionId":84960,"wgArticleId":4530,"wgIsArticle":!0,"wgIsRedirect":!1,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Articles","Cornea/External Disease","Glaucoma"],"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgRelevantPageName":"Management_of_Glaucoma_in_Eyes_with_Boston_Keratoprosthesis","wgRelevantArticleId":4530,
"wgIsProbablyEditable":!1,"wgRelevantPageIsProbablyEditable":!1,"wgRestrictionEdit":[],"wgRestrictionMove":[],"sdgDownArrowImage":"/w/extensions/SemanticDrilldown/skins/down-arrow.png","sdgRightArrowImage":"/w/extensions/SemanticDrilldown/skins/right-arrow.png","wgCiteDrawerEnableDesktop":!1,"wgCiteDrawerEnableMobile":!0,"wgCiteDrawerTheme":"dark","wgPageFormsTargetName":null,"wgPageFormsAutocompleteValues":[],"wgPageFormsAutocompleteOnAllChars":!1,"wgPageFormsFieldProperties":[],"wgPageFormsCargoFields":[],"wgPageFormsDependentFields":[],"wgPageFormsCalendarValues":[],"wgPageFormsCalendarParams":[],"wgPageFormsCalendarHTML":null,"wgPageFormsGridValues":[],"wgPageFormsGridParams":[],"wgPageFormsContLangYes":null,"wgPageFormsContLangNo":null,"wgPageFormsContLangMonths":[],"wgPageFormsHeightForMinimizingInstances":800,"wgPageFormsShowOnSelect":[],"wgPageFormsScriptPath":"/w/extensions/PageForms","edgValues":[],"wgPageFormsEDSettings":null,"wgAmericanDates":!0,
"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","pageVariantFallbacks":"en"},"srfFilteredConfig":null,"wgEditSubmitButtonLabelPublish":!1};RLSTATE={"site.styles":"ready","noscript":"ready","user.styles":"ready","user":"ready","user.options":"loading","ext.cite.styles":"ready","mediawiki.ui.button":"ready","skins.chameleon":"ready","zzz.ext.bootstrap.styles":"ready","mediawiki.toc.styles":"ready","ext.CookieWarning.styles":"ready","oojs-ui-core.styles":"ready","oojs-ui.styles.indicators":"ready","mediawiki.widgets.styles":"ready","oojs-ui-core.icons":"ready","ext.visualEditor.desktopArticleTarget.noscript":"ready","ext.srf.styles":"ready","ext.smw.style":"ready","ext.smw.tooltip.styles":"ready"};RLPAGEMODULES=["ext.smw.style","ext.smw.tooltips","ext.cite.ux-enhancements","smw.entityexaminer","site","mediawiki.page.startup","mediawiki.page.ready","mediawiki.toc","ext.citedrawer.main","ext.CookieWarning","ext.visualEditor.desktopArticleTarget.init",
"ext.visualEditor.targetLoader","ext.eyeWiki","ext.eyeWiki.slideshow","sentry.init","ext.bootstrap.scripts"];</script>
<script>(RLQ=window.RLQ||[]).push(function(){mw.loader.implement("user.options@1hzgi",function($,jQuery,require,module){/*@nomin*/mw.user.tokens.set({"patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"});
});});</script>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.CookieWarning.styles%7Cext.cite.styles%7Cext.visualEditor.desktopArticleTarget.noscript%7Cmediawiki.toc.styles%7Cmediawiki.ui.button%7Cmediawiki.widgets.styles%7Coojs-ui-core.icons%2Cstyles%7Coojs-ui.styles.indicators%7Cskins.chameleon%7Czzz.ext.bootstrap.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.smw.style%7Cext.smw.tooltip.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.srf.styles&amp;only=styles&amp;skin=chameleon"/>
<script async="" src="/w/load.php?lang=en&amp;modules=startup&amp;only=scripts&amp;raw=1&amp;skin=chameleon"></script>
<style>#mw-indicator-mw-helplink {display:none;}</style>
<meta name="ResourceLoaderDynamicStyles" content=""/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=site.styles&amp;only=styles&amp;skin=chameleon"/>
<meta name="generator" content="MediaWiki 1.35.8"/>
<meta name="description" content="Advances in keratoprosthesis implant design along with improvements in postoperative management have led to a decline in complications associated with keratoprosthesis&amp;#91;1&amp;#93;. However, while the incidence of implant extrusion, corneal necrosis, and infectious endophthalmitis have decreased, glaucoma remains a primary threat to visual prognosis in patients with a keratoprosthesis&amp;#91;2&amp;#93; &amp;#91;3&amp;#93;&amp;#91;4&amp;#93;. The Boston Keratoprosthesis (Kpro) is an artificial corneal transplant composed of polymethyl methacrylate (PMMA). It is available in two types; Type I Kpro is the most widely used and Type II Kpro is reserved for more severe ocular surface disease. Most of the available literature pertains to glaucoma management in eyes with Boston Type I Kpro."/>
<meta name="date" content="2022-09-11"/>
<meta name="WT.seg_1" content="0"/>
<meta name="google-site-verification" content="mtQvMIGqpWB4oyYM5mux15MHU-3qWI0bWtyRa2b5rlk"/>
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/>
<link rel="alternate" type="application/rdf+xml" title="Management of Glaucoma in Eyes with Boston Keratoprosthesis" href="/w/index.php?title=Special:ExportRDF/Management_of_Glaucoma_in_Eyes_with_Boston_Keratoprosthesis&amp;xmlmime=rdf"/>
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico"/>
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="EyeWiki (en)"/>
<link rel="EditURI" type="application/rsd+xml" href="https://eyewiki.org/w/api.php?action=rsd"/>
<link rel="preconnect" href="https://fonts.gstatic.com">
<link href="https://fonts.googleapis.com/css2?family=Lato:ital,wght@0,400;0,700;1,400&display=swap" rel="stylesheet">
<!-- Favicons MEYE-108 -->
<link rel="apple-touch-icon" sizes="120x120" href="/w/extensions/EyeWiki/favicons/apple-touch-icon.png">
<link rel="icon" type="image/png" sizes="32x32" href="/w/extensions/EyeWiki/favicons/favicon-32x32.png">
<link rel="icon" type="image/png" sizes="16x16" href="/w/extensions/EyeWiki/favicons/favicon-16x16.png">
<link rel="manifest" href="/w/extensions/EyeWiki/favicons/site.webmanifest">
<link rel="mask-icon" href="/w/extensions/EyeWiki/favicons/safari-pinned-tab.svg" color="#603cba">
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico">
<meta name="msapplication-TileColor" content="#603cba">
<meta name="msapplication-config" content="/w/extensions/EyeWiki/favicons/browserconfig.xml">
<meta name="theme-color" content="#ffffff">
<script> window.interdeal = { "sitekey": "81c701489fb8bb4ab90ca1cb0931f9c5", "Position": "Left", "Menulang": "EN", "domains": { "js": "https://cdn.equalweb.com/", "acc": "https://access.equalweb.com/" }, "btnStyle": { "vPosition": [ "80%", null ], "scale": [ "0.8", "0.8" ], "color": { "main": "#1876c9" }, "icon": { "type": 1, "outline": false } } }; (function(doc, head, body){ var coreCall = doc.createElement('script'); coreCall.src = 'https://cdn.equalweb.com/core/4.3.8/accessibility.js'; coreCall.defer = true; coreCall.integrity = 'sha512-u6i35wNTfRZXp0KDwSb3TntaIKI2ItCt/H/KcYIsBeVbaVMerEQLBnU5/ztfBg9aSW1gg7AN4CqCu9a455jkUg=='; coreCall.crossOrigin = 'anonymous'; coreCall.setAttribute('data-cfasync', true ); body? body.appendChild(coreCall) : head.appendChild(coreCall); })(document, document.head, document.body); </script>
<!--[if lt IE 9]><script src="/w/resources/lib/html5shiv/html5shiv.js"></script><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-Management_of_Glaucoma_in_Eyes_with_Boston_Keratoprosthesis rootpage-Management_of_Glaucoma_in_Eyes_with_Boston_Keratoprosthesis layout-standard skin-chameleon action-view">
	<div class="flex-fill container">
		<div class="row">
			<div class="flex-grow-0 col-12 col-cmln-6 d-flex flex-column flex-md-row w-md-100 justify-content-start align-items-center col">
					<div class="float-left mr-3 mb-2"><a href="//aao.org"><img id="aao-logo" src="/w/extensions/EyeWiki/skins/chameleon/AAO_Logo.png"></a></div>
                		
				<!-- logo and main page link -->
				<div id="p-logo" class="p-logo" role="banner">
					<a href="/Main_Page" title="Visit the main page"><img src="/w/extensions/EyeWiki/skins/chameleon/EyeWiki_Logo.png" alt="EyeWiki"/></a>
				</div>
			</div>
			<div class="ml-auto col-12 col-cmln col">
				<div class="row">
					<div class="col">
						<!-- personal tools -->
						<div class="p-personal pull-right" id="p-personal" >
							<ul class="p-personal-tools" >
								<li id="pt-createaccount"><a href="/w/index.php?title=Special:CreateAccount&amp;returnto=Management+of+Glaucoma+in+Eyes+with+Boston+Keratoprosthesis" title="You are encouraged to create an account and log in; however, it is not mandatory" class="pt-createaccount">Create account</a></li>
								<li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Management+of+Glaucoma+in+Eyes+with+Boston+Keratoprosthesis" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o" class="pt-login">Log in</a></li>
							</ul>
						</div>

					</div>
				</div>
				<div class="row">
					<div class="col">
						<!-- search form -->
						<div  id="p-search" class="p-search pull-right" role="search"  >
							<form  id="searchform" class="mw-search" action="/w/index.php" >
								<input type="hidden" name="title" value=" Special:Search" />
								<div class="input-group">
									<input name="search" placeholder="Search EyeWiki" title="Search EyeWiki [f]" accesskey="f" id="searchInput" class="form-control"/>
									<div class="input-group-append">
										<button value="Go" id="searchGoButton" name="go" type="submit" class="search-btn searchGoButton" aria-label="Go to page" title="Go to a page with this exact name if it exists"></button>
									</div>
								</div>
							</form>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar collapsible mb-3 mt-2 p-1 mt-cmln-0" role="navigation" id="mw-navigation">
					<button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#hbpzyw605q"></button>
					<div class="collapse navbar-collapse hbpzyw605q" id="hbpzyw605q">
						<div class="navbar-nav"><div class="nav-item"><a class="nav-link fas fa-home"  href="/Main_Page">Main Page</a></div><div class="nav-item"><a class="nav-link fas fa-book"  href="/Category:Articles">Articles</a></div><div class="nav-item"><a class="nav-link fas fa-play"  href="/Help:Getting_Started">Getting Started</a></div><div class="nav-item"><a class="nav-link fas fa-question"  href="/Help:Contents">Help</a></div><div class="nav-item"><a class="nav-link fas fa-backward"  href="/Special:RecentChanges">Recent changes</a></div><div class="nav-item"><a class="nav-link fas fa-door-open"  href="#">My Portal</a></div>
						</div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- Content navigation -->
				<div class="mb-3 pagetools p-contentnavigation" id="p-contentnavigation">
					<!-- namespaces -->
					<div id="p-namespaces" class="p-namespaces">
						<div class="tab-group">
							<div id="ca-nstab-main" class="selected"><a href="/Management_of_Glaucoma_in_Eyes_with_Boston_Keratoprosthesis" title="View the content page [c]" accesskey="c" class="selected ca-nstab-main">Page</a></div>
							<div id="ca-talk" class="new"><a href="/w/index.php?title=Talk:Management_of_Glaucoma_in_Eyes_with_Boston_Keratoprosthesis&amp;action=edit&amp;redlink=1" rel="discussion" title="Discussion about the content page (page does not exist) [t]" accesskey="t" class="new ca-talk">Discussion</a></div>
						</div>
					</div>
					<!-- views -->
					<div id="p-views" class="p-views">
						<div class="tab-group">
							<div id="ca-formedit"><a href="/w/index.php?title=Management_of_Glaucoma_in_Eyes_with_Boston_Keratoprosthesis&amp;action=formedit" title="Edit this page with a form [&amp;]" accesskey="&amp;" class="ca-formedit">View form</a></div>
							<div id="ca-viewsource"><a href="/w/index.php?title=Management_of_Glaucoma_in_Eyes_with_Boston_Keratoprosthesis&amp;action=edit" title="This page is protected.&#10;You can view its source [e]" accesskey="e" class="ca-viewsource">View source</a></div>
							<div id="ca-history"><a href="/w/index.php?title=Management_of_Glaucoma_in_Eyes_with_Boston_Keratoprosthesis&amp;action=history" title="Past revisions of this page [h]" accesskey="h" class="ca-history">History</a></div>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">

			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- start the content area -->
				<div id="content" class="mw-body content"><a id="top" class="top"></a>
					<div id="mw-indicators" class="mw-indicators">
					<div id="mw-indicator-smw-entity-examiner" class="mw-indicator mw-indicator-smw-entity-examiner"><div class="smw-entity-examiner smw-indicator-vertical-bar-loader" data-subject="Management_of_Glaucoma_in_Eyes_with_Boston_Keratoprosthesis#0##" data-dir="ltr" data-uselang="" title="Running an examiner in the background"></div></div>
				</div>
						<div class="contentHeader">
						<!-- title of the page -->
						<h1 id="firstHeading" class="firstHeading">Management of Glaucoma in Eyes with Boston Keratoprosthesis</h1>
						<!-- tagline; usually goes something like "From WikiName" primary purpose of this seems to be for printing to identify the source of the content -->
						<div id="siteSub" class="siteSub">From EyeWiki</div><div id="jump-to-nav" class="mw-jump jump-to-nav">Jump to:<a href="#mw-navigation">navigation</a>, <a href="#p-search">search</a></div>
					</div>
					<div id="bodyContent" class="bodyContent">
						<!-- body text -->

						<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><div class="mw-parser-output"><div id="article-header" data-description2-ignore=""><div id="contest" style="margin-bottom: 6px;">
</div>
<div class="infobox contributors">
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header"><a href="/Property:Authors" title="Property:Authors">Article initiated by</a>:
</div>
<div class="info-section-body"><a href="/User:Ariel.J.Tyring" title="User:Ariel.J.Tyring">Ariel J. Tyring, MD</a>,&#8201;<a href="/User:Joanne.C.Wen" title="User:Joanne.C.Wen">Joanne C.Wen, MD</a>,&#8201;<a href="/w/index.php?title=User:David_Booy_MS&amp;action=formedit&amp;redlink=1" class="new" title="User:David Booy MS (page does not exist)">David Booy MS</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">All authors and contributors:
</div>
<div class="info-section-body"> <a href="/User:Vatinee.Bunya" title="User:Vatinee.Bunya">Vatinee Y. Bunya, MD,  MSCE</a>,&#160;<a href="/User:Ariel.J.Tyring" title="User:Ariel.J.Tyring">Ariel J. Tyring, MD</a>,&#160;<a href="/User:Augustine.Hong" title="User:Augustine.Hong">Augustine Hong, MD</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Assigned editor:
</div>
<div class="info-section-body"> <a href="/User:Augustine.Hong" title="User:Augustine.Hong">Augustine Hong, MD</a>,&#32;<a href="/User:Ian.Conner" title="User:Ian.Conner">Ian Conner, MD, PhD</a></div>
</div><div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Review:
</div>
<div class="info-section-body">Assigned status <b>Up to Date</b>
</div>
</div>&#160;by <a href="/User:Augustine.Hong" title="User:Augustine.Hong">Augustine Hong, MD</a> on September 12, 2022.
</div>
<div style="display:none;">
<table cellspacing="5">

<tbody><tr>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Management_of_Glaucoma_in_Eyes_with_Boston_Keratoprosthesis&amp;action=formedit">add</a></small>
</td></tr>
<tr>
<th align="right"><b><a href="/Property:Contributing_Editors" title="Property:Contributing Editors">Contributing Editors</a>:</b>
</th>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Management_of_Glaucoma_in_Eyes_with_Boston_Keratoprosthesis&amp;action=formedit">add</a></small>
</td></tr>
</tbody></table> </div>
<div style="display:none;">
<p><br />
</p>
</div>
<div id="local-videos">
</div>
</div>
<div id="toc" class="toc" role="navigation" aria-labelledby="mw-toc-heading"><input type="checkbox" role="button" id="toctogglecheckbox" class="toctogglecheckbox" style="display:none" /><div class="toctitle" lang="en" dir="ltr"><h2 id="mw-toc-heading">Contents</h2><span class="toctogglespan"><label class="toctogglelabel" for="toctogglecheckbox"></label></span></div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Introduction"><span class="tocnumber">1</span> <span class="toctext">Introduction</span></a></li>
<li class="toclevel-1 tocsection-2"><a href="#Prevalence"><span class="tocnumber">2</span> <span class="toctext">Prevalence</span></a>
<ul>
<li class="toclevel-2 tocsection-3"><a href="#Incidence_of_Glaucoma_prior_to_Kpro_Surgery"><span class="tocnumber">2.1</span> <span class="toctext">Incidence of Glaucoma prior to Kpro Surgery</span></a></li>
<li class="toclevel-2 tocsection-4"><a href="#Incidence_of_Glaucoma_Following_Kpro_Surgery"><span class="tocnumber">2.2</span> <span class="toctext">Incidence of Glaucoma Following Kpro Surgery</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-5"><a href="#Pathophysiology"><span class="tocnumber">3</span> <span class="toctext">Pathophysiology</span></a></li>
<li class="toclevel-1 tocsection-6"><a href="#Diagnosis_and_Monitoring"><span class="tocnumber">4</span> <span class="toctext">Diagnosis and Monitoring</span></a>
<ul>
<li class="toclevel-2 tocsection-7"><a href="#Intraocular_Pressure_Measurement"><span class="tocnumber">4.1</span> <span class="toctext">Intraocular Pressure Measurement</span></a></li>
<li class="toclevel-2 tocsection-8"><a href="#Imaging"><span class="tocnumber">4.2</span> <span class="toctext">Imaging</span></a></li>
<li class="toclevel-2 tocsection-9"><a href="#Optic_Nerve"><span class="tocnumber">4.3</span> <span class="toctext">Optic Nerve</span></a></li>
<li class="toclevel-2 tocsection-10"><a href="#Perimetry"><span class="tocnumber">4.4</span> <span class="toctext">Perimetry</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-11"><a href="#Management"><span class="tocnumber">5</span> <span class="toctext">Management</span></a>
<ul>
<li class="toclevel-2 tocsection-12"><a href="#Medical_Treatment"><span class="tocnumber">5.1</span> <span class="toctext">Medical Treatment</span></a></li>
<li class="toclevel-2 tocsection-13"><a href="#Surgical_Treatment"><span class="tocnumber">5.2</span> <span class="toctext">Surgical Treatment</span></a></li>
<li class="toclevel-2 tocsection-14"><a href="#Cyclophotocoagulation"><span class="tocnumber">5.3</span> <span class="toctext">Cyclophotocoagulation</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-15"><a href="#References"><span class="tocnumber">6</span> <span class="toctext">References</span></a></li>
</ul>
</div>

<h1><span class="mw-headline" id="Introduction">Introduction</span></h1>
<p>Advances in keratoprosthesis implant design along with improvements in postoperative management have led to a decline in complications associated with keratoprosthesis<sup id="cite_ref-:0_1-0" class="reference"><a href="#cite_note-:0-1">&#91;1&#93;</a></sup>. However, while the incidence of implant extrusion, corneal necrosis, and infectious endophthalmitis have decreased, glaucoma remains a primary threat to visual prognosis in patients with a keratoprosthesis<sup id="cite_ref-:1_2-0" class="reference"><a href="#cite_note-:1-2">&#91;2&#93;</a></sup> <sup id="cite_ref-3" class="reference"><a href="#cite_note-3">&#91;3&#93;</a></sup><sup id="cite_ref-:2_4-0" class="reference"><a href="#cite_note-:2-4">&#91;4&#93;</a></sup>. The Boston Keratoprosthesis (Kpro) is an artificial corneal transplant composed of polymethyl methacrylate (PMMA). It is available in two types; Type I Kpro is the most widely used and Type II Kpro is reserved for more severe ocular surface disease. Most of the available literature pertains to glaucoma management in eyes with Boston Type I Kpro. 
</p>
<h1><span class="mw-headline" id="Prevalence">Prevalence</span></h1>
<h2><span class="mw-headline" id="Incidence_of_Glaucoma_prior_to_Kpro_Surgery">Incidence of Glaucoma prior to Kpro Surgery</span></h2>
<p>Outcome studies have found a pre-existing diagnosis of glaucoma in 36-76% of patients receiving Kpro and many had undergone prior glaucoma surgery<sup id="cite_ref-:0_1-1" class="reference"><a href="#cite_note-:0-1">&#91;1&#93;</a></sup><sup id="cite_ref-:3_5-0" class="reference"><a href="#cite_note-:3-5">&#91;5&#93;</a></sup><sup id="cite_ref-:4_6-0" class="reference"><a href="#cite_note-:4-6">&#91;6&#93;</a></sup><sup id="cite_ref-:5_7-0" class="reference"><a href="#cite_note-:5-7">&#91;7&#93;</a></sup><sup id="cite_ref-:6_8-0" class="reference"><a href="#cite_note-:6-8">&#91;8&#93;</a></sup><sup id="cite_ref-:7_9-0" class="reference"><a href="#cite_note-:7-9">&#91;9&#93;</a></sup><sup id="cite_ref-:8_10-0" class="reference"><a href="#cite_note-:8-10">&#91;10&#93;</a></sup><sup id="cite_ref-11" class="reference"><a href="#cite_note-11">&#91;11&#93;</a></sup><sup id="cite_ref-12" class="reference"><a href="#cite_note-12">&#91;12&#93;</a></sup><sup id="cite_ref-13" class="reference"><a href="#cite_note-13">&#91;13&#93;</a></sup>. In some cases, the underlying ocular conditions that contributed to corneal decompensation necessitating a Kpro also confer an increased risk of glaucoma. In addition to a multitude of corneal and anterior segment complications, herpes simplex virus (HSV) infection is associated with trabeculitis and increased intraocular pressure. One cohort study of 17 eyes with KPro following HSV keratitis found that 66% had glaucoma preoperatively<sup id="cite_ref-14" class="reference"><a href="#cite_note-14">&#91;14&#93;</a></sup>.  Stevens Johnson Syndrome (SJS) is also associated with increased glaucoma risk. Sayegh et al found glaucoma preoperatively in 75% of KPro eyes with severe anterior segment inflammation and scarring from SJS<sup id="cite_ref-15" class="reference"><a href="#cite_note-15">&#91;15&#93;</a></sup>.  Cade et al report preoperative glaucoma in 75% of eyes with KPro caused by chemical burns. Alkali burns in particular are associated with severe glaucoma. Alkaline material penetrates deeper into the eye than other substances and damages angle structures, which leads to scarring and outflow obstruction<sup id="cite_ref-:9_16-0" class="reference"><a href="#cite_note-:9-16">&#91;16&#93;</a></sup>.  Harissi-Dagher et al. found that eyes with alkaline injuries may continue to have progressive optic nerve damage despite adequate intraocular pressure control with glaucoma drainage devices (GDD)<sup id="cite_ref-17" class="reference"><a href="#cite_note-17">&#91;17&#93;</a></sup>. Finally, prior failed penetrating keratoplasty (PKP) transplant, which is common in many KPro recipients, is a risk factor for glaucoma because PKP may cause synechiae formation and chronic angle closure<sup id="cite_ref-:3_5-1" class="reference"><a href="#cite_note-:3-5">&#91;5&#93;</a></sup>. 
</p>
<h2><span class="mw-headline" id="Incidence_of_Glaucoma_Following_Kpro_Surgery">Incidence of Glaucoma Following Kpro Surgery</span></h2>
<p>Glaucoma in Kpro eyes is often advanced at the time of keratoprosthesis implantation and demonstrates a more aggressive course with disease progression exacerbated by perioperative inflammation<sup id="cite_ref-:10_18-0" class="reference"><a href="#cite_note-:10-18">&#91;18&#93;</a></sup>. Following KPro surgery, 14-28% of patients have elevated IOP<sup id="cite_ref-:0_1-2" class="reference"><a href="#cite_note-:0-1">&#91;1&#93;</a></sup><sup id="cite_ref-:5_7-1" class="reference"><a href="#cite_note-:5-7">&#91;7&#93;</a></sup><sup id="cite_ref-:2_4-1" class="reference"><a href="#cite_note-:2-4">&#91;4&#93;</a></sup><sup id="cite_ref-:6_8-1" class="reference"><a href="#cite_note-:6-8">&#91;8&#93;</a></sup><sup id="cite_ref-:7_9-1" class="reference"><a href="#cite_note-:7-9">&#91;9&#93;</a></sup><sup id="cite_ref-:11_19-0" class="reference"><a href="#cite_note-:11-19">&#91;19&#93;</a></sup>. Glaucomatous damage progresses in 7-14% of patients after KPro<sup id="cite_ref-:0_1-3" class="reference"><a href="#cite_note-:0-1">&#91;1&#93;</a></sup><sup id="cite_ref-:2_4-2" class="reference"><a href="#cite_note-:2-4">&#91;4&#93;</a></sup><sup id="cite_ref-:12_20-0" class="reference"><a href="#cite_note-:12-20">&#91;20&#93;</a></sup>. Development of glaucoma de novo following Kpro placement has been reported in 2-28% of KPro recipients<sup id="cite_ref-:0_1-4" class="reference"><a href="#cite_note-:0-1">&#91;1&#93;</a></sup><sup id="cite_ref-:2_4-3" class="reference"><a href="#cite_note-:2-4">&#91;4&#93;</a></sup><sup id="cite_ref-:6_8-2" class="reference"><a href="#cite_note-:6-8">&#91;8&#93;</a></sup><sup id="cite_ref-:7_9-2" class="reference"><a href="#cite_note-:7-9">&#91;9&#93;</a></sup><sup id="cite_ref-:11_19-1" class="reference"><a href="#cite_note-:11-19">&#91;19&#93;</a></sup><sup id="cite_ref-21" class="reference"><a href="#cite_note-21">&#91;21&#93;</a></sup>. Crnej et al found a rate of cup to disc ratio (C/D) progression of 0.075 per year in glaucomatous KPro eyes, which is approximately 7 times faster than the rate of C/D progression in patients with primary open angle glaucoma<sup id="cite_ref-:10_18-1" class="reference"><a href="#cite_note-:10-18">&#91;18&#93;</a></sup>. Some studies have found an increase in number of glaucoma medications used to control IOP following KPro implantation while others have reported a decrease<sup id="cite_ref-:4_6-1" class="reference"><a href="#cite_note-:4-6">&#91;6&#93;</a></sup><sup id="cite_ref-:7_9-3" class="reference"><a href="#cite_note-:7-9">&#91;9&#93;</a></sup><sup id="cite_ref-:8_10-1" class="reference"><a href="#cite_note-:8-10">&#91;10&#93;</a></sup>. 
</p>
<h1><span class="mw-headline" id="Pathophysiology">Pathophysiology</span></h1>
<p>A number of mechanisms for glaucoma development and progression in KPro eyes have been proposed. As noted by Crnej et al, eyes undergoing Kpro implantation often have pre-existing anterior segment damage due to an aggressive inflammatory process or traumatic event. It remains unclear if the Kpro surgery itself confers a unique glaucoma risk or if glaucoma simply develops as a consequence of further surgical trauma to already diseased eyes<sup id="cite_ref-:10_18-2" class="reference"><a href="#cite_note-:10-18">&#91;18&#93;</a></sup>. 
</p><p>Chronic angle closure (CACG) results from peripheral anterior synechiae formation caused by chronic inflammation or following surgery, especially amongst patients who have failed one or more prior PKP surgeries<sup id="cite_ref-:3_5-2" class="reference"><a href="#cite_note-:3-5">&#91;5&#93;</a></sup>. Netland et al used ultrasound biomicroscopy (UBM) to visualize posterior anterior synechiae following Kpro placement in eyes with glaucomatous optic neuropathy due to chronic angle closure<sup id="cite_ref-:0_1-5" class="reference"><a href="#cite_note-:0-1">&#91;1&#93;</a></sup>. Larger implant backplates clamp surgical wounds and reduce PAS formation<sup id="cite_ref-22" class="reference"><a href="#cite_note-22">&#91;22&#93;</a></sup>. However, larger implant backplates cause more congestion in the anterior chamber, which may impede aqueous outflow<sup id="cite_ref-:4_6-2" class="reference"><a href="#cite_note-:4-6">&#91;6&#93;</a></sup>. 
</p><p>Some have suggested removal of lens or iris to decrease complications from retroprosthetic membrane growth or PAS formation. Netland et al. removed iris tissue during Kpro placement in an attempt to decrease PAS and CACG. However, 21 of 36 eyes (58%) still developed glaucoma postoperatively in this series<sup id="cite_ref-:0_1-6" class="reference"><a href="#cite_note-:0-1">&#91;1&#93;</a></sup>. Others suggest that removal of iris may distort the angle and lead to collapse of the trabecular meshwork with resultant outflow obstruction<sup id="cite_ref-:3_5-3" class="reference"><a href="#cite_note-:3-5">&#91;5&#93;</a></sup>. Furthermore, a residual iris stump after resection may cause angle closure, similar to the mechanism for glaucoma observed in patients with congenital aniridia<sup id="cite_ref-:3_5-4" class="reference"><a href="#cite_note-:3-5">&#91;5&#93;</a></sup>.
</p><p>Inflammatory debris or vitreous material may obstruct the trabecular meshwork<sup id="cite_ref-:4_6-3" class="reference"><a href="#cite_note-:4-6">&#91;6&#93;</a></sup>. Perioperative inflammation stimulates release of cytokines, which can cause direct damage to and/or cause apoptosis of retinal ganglion cells. This theory is supported by the presence of optic disc pallor in many Kpro patients<sup id="cite_ref-:10_18-3" class="reference"><a href="#cite_note-:10-18">&#91;18&#93;</a></sup>. 
</p><p>Talajic et al propose that the Kpro implant causes surrounding tissue disruption and affects scleral rigidity. Alternation of scleral integrity can cause biomechanical damage to the optic nerve at the level of the lamina cribrosa<sup id="cite_ref-:4_6-4" class="reference"><a href="#cite_note-:4-6">&#91;6&#93;</a></sup>. This may help explain progression of optic neuropathy despite adequate IOP control in Kpro patients. 
</p><p>Finally, following Kpro implantation there is decreased ocular surface area which results in decreased absorption and reduced effectiveness of IOP-lowering medications. Perioperative steroids can influence glaucoma development or progression due to steroid-induced ocular hypertension. 
</p>
<h1><span class="mw-headline" id="Diagnosis_and_Monitoring">Diagnosis and Monitoring</span></h1>
<h2><span class="mw-headline" id="Intraocular_Pressure_Measurement">Intraocular Pressure Measurement</span></h2>
<p>Detection and monitoring of glaucoma after implantation of a Kpro poses many challenges, particularly when attempting to assess intraocular pressure. Applanation and handheld tonometers are inaccurate when applied over the Kpro. Handheld tonometer readings recorded from the limbus may be an alternative and comparison with limbus measurements from the fellow eye is recommended for interpretation of readings.  
</p><p>IOP estimation by finger tension or palpation, while being careful to avoid palpation over a GDD plate, is a commonly used method. The examiner should consider that GDD placement may alter scleral dynamics and complicate IOP estimation via palpation<sup id="cite_ref-:2_4-4" class="reference"><a href="#cite_note-:2-4">&#91;4&#93;</a></sup>. Some studies report that amongst experienced practitioners digital palpation can accurately detect IOP greater than 30 mmHg and within a margin of error of 5 mmHg<sup id="cite_ref-:13_23-0" class="reference"><a href="#cite_note-:13-23">&#91;23&#93;</a></sup><sup id="cite_ref-24" class="reference"><a href="#cite_note-24">&#91;24&#93;</a></sup><sup id="cite_ref-25" class="reference"><a href="#cite_note-25">&#91;25&#93;</a></sup>. Baum et al, however, report that digital palpation is generally inaccurate but useful for detection of markedly elevated IOP. They found little correlation between digital palpation and Goldmann tonometry readings<sup id="cite_ref-:13_23-1" class="reference"><a href="#cite_note-:13-23">&#91;23&#93;</a></sup>. Netland et al. reported that pneumotonometer and handheld tonometer use on sclera in Kpro patients overestimated IOP and digital palpation was the preferred method of IOP assessment in their study<sup id="cite_ref-:0_1-7" class="reference"><a href="#cite_note-:0-1">&#91;1&#93;</a></sup>. However, Kuo et al. found that although scleral pneumatonometry averaged 9 mmHg higher than corneal pneumatonometry, there was a linear correlation between the two over serial measurements<sup id="cite_ref-26" class="reference"><a href="#cite_note-26">&#91;26&#93;</a></sup>. Kapamajian et al. extrapolated an equation for corneal pneumatonometry (IOPk) from scleral pneumatonometry (IOPs) where IOPk = 11.9 + 0.32(IOPs) – 0.05(Age), which may allow scleral pneumatonometry to be used as an adequate alternative when corneal measurements are unreliable<sup id="cite_ref-27" class="reference"><a href="#cite_note-27">&#91;27&#93;</a></sup>. Finally, Estrovich et al. found that the Schiotz tonometer, when used on the temporal sclera or corneoscleral limbus, had higher accuracy than handheld tonometry or digital manometry<sup id="cite_ref-28" class="reference"><a href="#cite_note-28">&#91;28&#93;</a></sup>. 
</p>
<h2><span class="mw-headline" id="Imaging">Imaging</span></h2>
<p>Anterior segment optical coherence tomography (OCT) can be employed to evaluate angle structures in Kpro eyes. Garcia et al found that anterior segment OCT was superior to UBM for visualizing angle structures but inferior to UBM in assessment of GDD positioning in the sulcus<sup id="cite_ref-:12_20-1" class="reference"><a href="#cite_note-:12-20">&#91;20&#93;</a></sup>. As with other forms of glaucoma, serial optic nerve head (ONH) OCT and optic disc photos are recommended to evaluate for disease progression. Posterior segment and macular OCT may detect cystoid macular edema (CME), a frequent complication in this patient population<sup id="cite_ref-29" class="reference"><a href="#cite_note-29">&#91;29&#93;</a></sup>.  
</p>
<h2><span class="mw-headline" id="Optic_Nerve">Optic Nerve</span></h2>
<p>The clear optic of the keratoprosthesis implant allows direct visualization of the optic nerve and fundus for assessment of optic nerve health and C/D ratio changes. Preoperative visualization of optic nerve is often limited by corneal of intraocular media opacity<sup id="cite_ref-:2_4-5" class="reference"><a href="#cite_note-:2-4">&#91;4&#93;</a></sup>.  
</p>
<h2><span class="mw-headline" id="Perimetry">Perimetry</span></h2>
<p>The maximum Goldmann visual field in one series of Kpro patients was 90-95 degrees<sup id="cite_ref-30" class="reference"><a href="#cite_note-30">&#91;30&#93;</a></sup>. Functional testing with visual fields was found to be more reliable than structural testing with Heidelberg Retinal Tomography<sup id="cite_ref-:7_9-4" class="reference"><a href="#cite_note-:7-9">&#91;9&#93;</a></sup>. 
</p>
<h1><span class="mw-headline" id="Management">Management</span></h1>
<h2><span class="mw-headline" id="Medical_Treatment">Medical Treatment</span></h2>
<p>Because of the reduced ocular surface available for absorption following Kpro placement, topical IOP-lowering medications are less effective. Netland et al report preferred use of systemic carbonic anhydrase inhibitors when medical therapy is required for IOP control<sup id="cite_ref-:0_1-8" class="reference"><a href="#cite_note-:0-1">&#91;1&#93;</a></sup>. 
</p>
<h2><span class="mw-headline" id="Surgical_Treatment">Surgical Treatment</span></h2>
<p>Approximately 13 - 42% of patients required surgical treatment for glaucoma following Kpro placement<sup id="cite_ref-:0_1-9" class="reference"><a href="#cite_note-:0-1">&#91;1&#93;</a></sup><sup id="cite_ref-:2_4-6" class="reference"><a href="#cite_note-:2-4">&#91;4&#93;</a></sup><sup id="cite_ref-:5_7-2" class="reference"><a href="#cite_note-:5-7">&#91;7&#93;</a></sup><sup id="cite_ref-:6_8-3" class="reference"><a href="#cite_note-:6-8">&#91;8&#93;</a></sup><sup id="cite_ref-:7_9-5" class="reference"><a href="#cite_note-:7-9">&#91;9&#93;</a></sup><sup id="cite_ref-:11_19-2" class="reference"><a href="#cite_note-:11-19">&#91;19&#93;</a></sup><sup id="cite_ref-31" class="reference"><a href="#cite_note-31">&#91;31&#93;</a></sup>. Crnej et al found that when glaucoma surgery was performed prior to or concurrently with Kpro implantation there were significantly slower rates of C/D progression compared to eyes that received delayed surgical glaucoma treatment<sup id="cite_ref-:10_18-4" class="reference"><a href="#cite_note-:10-18">&#91;18&#93;</a></sup>. Lenis et al. found that, when compared to Kpro surgery alone, Kpro surgery combined with GDD placement resulted in improved IOP at 1 year<sup id="cite_ref-32" class="reference"><a href="#cite_note-32">&#91;32&#93;</a></sup>. Therefore, concurrent placement of GDD with Kpro surgery should be considered for eyes at increased risk of glaucomatous progression. 
</p><p>Valved GDD (Ahmed tube shunt) is the most commonly used drainage device amongst Kpro patients requiring surgical treatment for glaucoma<sup id="cite_ref-:1_2-1" class="reference"><a href="#cite_note-:1-2">&#91;2&#93;</a></sup><sup id="cite_ref-:3_5-5" class="reference"><a href="#cite_note-:3-5">&#91;5&#93;</a></sup>. Non-valved GDD can have more substantial IOP-lowering effect than valved GDD, but carry greater risk of hypotony from overfiltration<sup id="cite_ref-:0_1-10" class="reference"><a href="#cite_note-:0-1">&#91;1&#93;</a></sup><sup id="cite_ref-:1_2-2" class="reference"><a href="#cite_note-:1-2">&#91;2&#93;</a></sup>. Non-valved GDD also require several weeks of hypertensive phase to prevent hypotony, which may allow for interval glaucoma progression. The delay in IOP-lowering with non-valved GDD is especially troublesome because topical medications are less effective in Kpro eyes, which can lead to marked ocular hypertension postoperatively. Trabeculectomies are less effective because of tissue scarring adjacent to keratoprostheses<sup id="cite_ref-:0_1-11" class="reference"><a href="#cite_note-:0-1">&#91;1&#93;</a></sup>. Use of Ahmed GDD is generally recommended in all Kpro patients with glaucoma except in cases of primary open angle glaucoma or with normalized IOP not requiring medications. GDD placement 3-6 months prior to the Kpro implantation is sufficient to allow maturation of the GDD. If iris tissue or lens is removed during implantation of a Kpro, a pars plana vitrectomy should be performed and a GDD should be placed (9). For intact iris tissue it is recommended to perform a peripheral iridectomy concurrently<sup id="cite_ref-:2_4-7" class="reference"><a href="#cite_note-:2-4">&#91;4&#93;</a></sup>. Following Kpro surgery, Cade et al favor placement of GDD for digital palpation IOP estimates near 20 mmHg<sup id="cite_ref-:9_16-1" class="reference"><a href="#cite_note-:9-16">&#91;16&#93;</a></sup>. Netland et al report that GDD placement in Kpro patients successfully decreased IOP in nearly all cases<sup id="cite_ref-:0_1-12" class="reference"><a href="#cite_note-:0-1">&#91;1&#93;</a></sup>.  
</p><p>Some surgeons recommend tube placement in the sulcus to prevent anterior chamber crowding.  The GDD may be placed with a long tube in a radial orientation so that the tip may be visible in the sulcus<sup id="cite_ref-:3_5-6" class="reference"><a href="#cite_note-:3-5">&#91;5&#93;</a></sup>. Netland et al report that tube occlusion was the most common complication, observed in 11% of this cohort<sup id="cite_ref-:0_1-13" class="reference"><a href="#cite_note-:0-1">&#91;1&#93;</a></sup>. GDD placement in the sulcus decreases risk of tube exposure due to reduced contact with the implant backplate<sup id="cite_ref-:3_5-7" class="reference"><a href="#cite_note-:3-5">&#91;5&#93;</a></sup>. Risk of tube exposure can be decreased further with use of a patch graft. If the GDD is placed in the anterior chamber, Kamyar et al suggest use of posterior chamber intraocular lens to protect against tube occlusion from anterior migration of the vitreous<sup id="cite_ref-:8_10-2" class="reference"><a href="#cite_note-:8-10">&#91;10&#93;</a></sup>. 
</p><p>Other complications include formation of a fibrous capsule surrounding the GDD, which decreases effectiveness of the tube. This is observed more commonly in cicatrizing conjunctival disease<sup id="cite_ref-:11_19-3" class="reference"><a href="#cite_note-:11-19">&#91;19&#93;</a></sup>. Alternate epithelium lined drainage locations including the lacrimal sac and the maxillary and ethmoid sinuses have been suggested on the basis of a theoretical benefit of decreased fibrosis surrounding the drainage plate, but no significant IOP reduction has been demonstrated<sup id="cite_ref-33" class="reference"><a href="#cite_note-33">&#91;33&#93;</a></sup>. 
</p>
<h2><span class="mw-headline" id="Cyclophotocoagulation">Cyclophotocoagulation</span></h2>
<p>Cyclophotocoagulation (CPC) uses a diode laser to ablate the ciliary process, decrease aqueous production, and lower IOP. This can be accomplished transsclerally or endoscopically under direct visualization. Transscleral illumination with a fiberoptic light can be used to help guide location choice for transscleral CPC, but excessive scar tissue on the ocular surface may limit the utility of this technique<sup id="cite_ref-:11_19-4" class="reference"><a href="#cite_note-:11-19">&#91;19&#93;</a></sup>. Both endoscopic and transscleral forms of CPC are effective<sup id="cite_ref-:11_19-5" class="reference"><a href="#cite_note-:11-19">&#91;19&#93;</a></sup><sup id="cite_ref-34" class="reference"><a href="#cite_note-34">&#91;34&#93;</a></sup><sup id="cite_ref-35" class="reference"><a href="#cite_note-35">&#91;35&#93;</a></sup><sup id="cite_ref-36" class="reference"><a href="#cite_note-36">&#91;36&#93;</a></sup>. Semchyshyn et al found that transscleral CPC lowered IOP by approximately 60%<sup id="cite_ref-37" class="reference"><a href="#cite_note-37">&#91;37&#93;</a></sup>. A single transscleral CPC treatment resulted in normalized IOP at 48 months from treatment in 12 of 18 patients in one study by Rivier et al<sup id="cite_ref-:11_19-6" class="reference"><a href="#cite_note-:11-19">&#91;19&#93;</a></sup>. 
</p><p>Compared to GDD, CPC has the benefit of no permanent hardware, and therefore no implant exposure and less risk of endophthalmitis. Talajic et al propose endoscopic CPC as an alternative first line glaucoma treatment in Kpro eyes because of fewer complications compared to surgery<sup id="cite_ref-:4_6-5" class="reference"><a href="#cite_note-:4-6">&#91;6&#93;</a></sup>.  Disadvantages to CPC include difficult titration requiring multiple procedures for adequate IOP control<sup id="cite_ref-:3_5-8" class="reference"><a href="#cite_note-:3-5">&#91;5&#93;</a></sup>. Excessive ciliary body damage from CPC can result in hypotony and, rarely, phthisis bulbi, though hypotony and phthisis may also occur as a result of GDD overfiltration<sup id="cite_ref-:9_16-2" class="reference"><a href="#cite_note-:9-16">&#91;16&#93;</a></sup>. 
</p><p>CPC is a good therapeutic option for type II keratoprothesis in which the conjunctiva has been resected and filtration surgery is not possible or in cases of type I keratoprosthesis if the conjunctiva is sufficiently scarred<sup id="cite_ref-:0_1-14" class="reference"><a href="#cite_note-:0-1">&#91;1&#93;</a></sup>.
</p><p>Endoscopic cyclophotocoagulation has also been reported with small case series reporting stable long-term IOP in 5 out of 7 patients. <sup id="cite_ref-38" class="reference"><a href="#cite_note-38">&#91;38&#93;</a></sup>
</p>
<h1><span class="mw-headline" id="References">References</span></h1>
<div class="mw-references-wrap mw-references-columns"><ol class="references">
<li id="cite_note-:0-1"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:0_1-0">1.00</a></sup> <sup><a href="#cite_ref-:0_1-1">1.01</a></sup> <sup><a href="#cite_ref-:0_1-2">1.02</a></sup> <sup><a href="#cite_ref-:0_1-3">1.03</a></sup> <sup><a href="#cite_ref-:0_1-4">1.04</a></sup> <sup><a href="#cite_ref-:0_1-5">1.05</a></sup> <sup><a href="#cite_ref-:0_1-6">1.06</a></sup> <sup><a href="#cite_ref-:0_1-7">1.07</a></sup> <sup><a href="#cite_ref-:0_1-8">1.08</a></sup> <sup><a href="#cite_ref-:0_1-9">1.09</a></sup> <sup><a href="#cite_ref-:0_1-10">1.10</a></sup> <sup><a href="#cite_ref-:0_1-11">1.11</a></sup> <sup><a href="#cite_ref-:0_1-12">1.12</a></sup> <sup><a href="#cite_ref-:0_1-13">1.13</a></sup> <sup><a href="#cite_ref-:0_1-14">1.14</a></sup></span> <span class="reference-text">1.Netland, Peter A., Hisao Terada, and Claes H. Dohlman. "Glaucoma associated with keratoprosthesis."&#160;Ophthalmology&#160;105.4 (1998): 751-757.</span>
</li>
<li id="cite_note-:1-2"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:1_2-0">2.0</a></sup> <sup><a href="#cite_ref-:1_2-1">2.1</a></sup> <sup><a href="#cite_ref-:1_2-2">2.2</a></sup></span> <span class="reference-text">2. Yaghouti F, Nouri M, Abad JC, et al., Keratoprosthesis: preoperative prognostic categories, Cornea, 1998;20(1):19–23.</span>
</li>
<li id="cite_note-3"><span class="mw-cite-backlink"><a href="#cite_ref-3">↑</a></span> <span class="reference-text">Ma JJ, Graney JM, Dohlman CH, Repeat penetrating keratoplasty versus the Boston keratoprosthesis in graft failure, Int Ophthalmol Clin, 2005;45(4):49–59.</span>
</li>
<li id="cite_note-:2-4"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:2_4-0">4.0</a></sup> <sup><a href="#cite_ref-:2_4-1">4.1</a></sup> <sup><a href="#cite_ref-:2_4-2">4.2</a></sup> <sup><a href="#cite_ref-:2_4-3">4.3</a></sup> <sup><a href="#cite_ref-:2_4-4">4.4</a></sup> <sup><a href="#cite_ref-:2_4-5">4.5</a></sup> <sup><a href="#cite_ref-:2_4-6">4.6</a></sup> <sup><a href="#cite_ref-:2_4-7">4.7</a></sup></span> <span class="reference-text">Chew HF, Ayres BD, Hammersmith KM, et al., Boston keratoprosthesis outcomes and complications, Cornea, 2009;28(9):989–96.</span>
</li>
<li id="cite_note-:3-5"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:3_5-0">5.0</a></sup> <sup><a href="#cite_ref-:3_5-1">5.1</a></sup> <sup><a href="#cite_ref-:3_5-2">5.2</a></sup> <sup><a href="#cite_ref-:3_5-3">5.3</a></sup> <sup><a href="#cite_ref-:3_5-4">5.4</a></sup> <sup><a href="#cite_ref-:3_5-5">5.5</a></sup> <sup><a href="#cite_ref-:3_5-6">5.6</a></sup> <sup><a href="#cite_ref-:3_5-7">5.7</a></sup> <sup><a href="#cite_ref-:3_5-8">5.8</a></sup></span> <span class="reference-text">Banitt M, Evaluation and management of glaucoma after keratoprosthesis, Curr Opin Ophthalmol, 2011;22:133–6.</span>
</li>
<li id="cite_note-:4-6"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:4_6-0">6.0</a></sup> <sup><a href="#cite_ref-:4_6-1">6.1</a></sup> <sup><a href="#cite_ref-:4_6-2">6.2</a></sup> <sup><a href="#cite_ref-:4_6-3">6.3</a></sup> <sup><a href="#cite_ref-:4_6-4">6.4</a></sup> <sup><a href="#cite_ref-:4_6-5">6.5</a></sup></span> <span class="reference-text">Talajic JC, Agoumi Y, Gagné S, et al., Prevalence, progression, and impact of glaucoma on vision after Boston type 1 keratoprosthesis surgery, Am J Ophthalmol, 2012;153(2):267–74</span>
</li>
<li id="cite_note-:5-7"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:5_7-0">7.0</a></sup> <sup><a href="#cite_ref-:5_7-1">7.1</a></sup> <sup><a href="#cite_ref-:5_7-2">7.2</a></sup></span> <span class="reference-text">Aldave AJ, Kamal KM, Vo RC, Yu F. The Boston type I keratoprosthesis: improving outcomes and expanding indications. Ophthalmology 2009; 116:640 – 651.</span>
</li>
<li id="cite_note-:6-8"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:6_8-0">8.0</a></sup> <sup><a href="#cite_ref-:6_8-1">8.1</a></sup> <sup><a href="#cite_ref-:6_8-2">8.2</a></sup> <sup><a href="#cite_ref-:6_8-3">8.3</a></sup></span> <span class="reference-text">Bradley JC, Hernandez EG, Schwab IR, Mannis MJ. Boston type 1 keratoprosthesis: the University of California Davis experience. Cornea 2009; 28:321 – 327.</span>
</li>
<li id="cite_note-:7-9"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:7_9-0">9.0</a></sup> <sup><a href="#cite_ref-:7_9-1">9.1</a></sup> <sup><a href="#cite_ref-:7_9-2">9.2</a></sup> <sup><a href="#cite_ref-:7_9-3">9.3</a></sup> <sup><a href="#cite_ref-:7_9-4">9.4</a></sup> <sup><a href="#cite_ref-:7_9-5">9.5</a></sup></span> <span class="reference-text">Zerbe BL, Belin MW, Ciolino JB. Results from the multicenter Boston Type 1 Keratoprosthesis Study. Ophthalmology 2006; 113:1779; e1771–e1777.</span>
</li>
<li id="cite_note-:8-10"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:8_10-0">10.0</a></sup> <sup><a href="#cite_ref-:8_10-1">10.1</a></sup> <sup><a href="#cite_ref-:8_10-2">10.2</a></sup></span> <span class="reference-text">Kamyar R, Weizer JS, de Paula FH, et al. Glaucoma associated with Boston type I keratoprosthesis. Cornea. 2012;31:134–139.</span>
</li>
<li id="cite_note-11"><span class="mw-cite-backlink"><a href="#cite_ref-11">↑</a></span> <span class="reference-text">Robert MC, Pomerleau V, Harissi-Dagher M. Complications associated with Boston keratoprosthesis type 1 and glaucoma drainage devices. Br J Ophthalmol. 2013;97:573–577.</span>
</li>
<li id="cite_note-12"><span class="mw-cite-backlink"><a href="#cite_ref-12">↑</a></span> <span class="reference-text">Aldave AJ, Sangwan VS, Basu S, et al. International results with the Boston type I keratoprosthesis. Ophthalmology. 2012;119:1530–1538.</span>
</li>
<li id="cite_note-13"><span class="mw-cite-backlink"><a href="#cite_ref-13">↑</a></span> <span class="reference-text">Patel AP, Wu EI, Ritterband DC, et al. Boston type 1 keratoprosthesis: the New York Eye and Ear experience. Eye (Lond). 2012;26:418–425.</span>
</li>
<li id="cite_note-14"><span class="mw-cite-backlink"><a href="#cite_ref-14">↑</a></span> <span class="reference-text">Khan BF, Harissi-Dagher M, Pavan-Langston D, et al., The Boston Keratoprosthesis in Herpetic Keratitis, Arch Ophthalmol, 2007;125:745–9.</span>
</li>
<li id="cite_note-15"><span class="mw-cite-backlink"><a href="#cite_ref-15">↑</a></span> <span class="reference-text">Sayegh RR, Ang LPK, Foster CS, Dohlman CH, The Boston Keratoprosthesis in Stevens-Johnson syndrome, Am J Ophthalmol, 2008;145:438–44.</span>
</li>
<li id="cite_note-:9-16"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:9_16-0">16.0</a></sup> <sup><a href="#cite_ref-:9_16-1">16.1</a></sup> <sup><a href="#cite_ref-:9_16-2">16.2</a></sup></span> <span class="reference-text">Cade F, Grosskreutz CL, Tauber A, Dohlman CH, Glaucoma in eyes with severe chemical burn, before and after keratoprosthesis, Cornea, 2011;30(12):1322–7.</span>
</li>
<li id="cite_note-17"><span class="mw-cite-backlink"><a href="#cite_ref-17">↑</a></span> <span class="reference-text">Harissi-Dagher M, Dohlman CH, The Boston Keratoprosthesis in severe ocular trauma, Can J Ophthalmol, 2008;43(2):165–9.</span>
</li>
<li id="cite_note-:10-18"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:10_18-0">18.0</a></sup> <sup><a href="#cite_ref-:10_18-1">18.1</a></sup> <sup><a href="#cite_ref-:10_18-2">18.2</a></sup> <sup><a href="#cite_ref-:10_18-3">18.3</a></sup> <sup><a href="#cite_ref-:10_18-4">18.4</a></sup></span> <span class="reference-text">Crnej, Alja, et al. "Glaucoma progression and role of glaucoma surgery in patients with Boston keratoprosthesis." Cornea 33.4 (2014): 349-354.</span>
</li>
<li id="cite_note-:11-19"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:11_19-0">19.0</a></sup> <sup><a href="#cite_ref-:11_19-1">19.1</a></sup> <sup><a href="#cite_ref-:11_19-2">19.2</a></sup> <sup><a href="#cite_ref-:11_19-3">19.3</a></sup> <sup><a href="#cite_ref-:11_19-4">19.4</a></sup> <sup><a href="#cite_ref-:11_19-5">19.5</a></sup> <sup><a href="#cite_ref-:11_19-6">19.6</a></sup></span> <span class="reference-text">Rivier D, Paula JS, Kim E, et al. Glaucoma and
keratoprosthesis surgery: role of adjunctive cyclophotocoagulation. J Glaucoma
2009; 18:321–324.&#160; &#160;&#160;</span>
</li>
<li id="cite_note-:12-20"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:12_20-0">20.0</a></sup> <sup><a href="#cite_ref-:12_20-1">20.1</a></sup></span> <span class="reference-text">Vora, Gargi Khare, and Kathryn A. Colby. "Management of glaucoma following Boston keratoprosthesis." E<i>ur Ophthal Rev</i> 6 (2012): 214-217.</span>
</li>
<li id="cite_note-21"><span class="mw-cite-backlink"><a href="#cite_ref-21">↑</a></span> <span class="reference-text">Patel AP, Wu EI, Ritterband DC, et al. Boston type 1 keratoprosthesis: the New York Eye and Ear experience. <i>Eye (Lond)</i>. 2012;26:418–425. </span>
</li>
<li id="cite_note-22"><span class="mw-cite-backlink"><a href="#cite_ref-22">↑</a></span> <span class="reference-text"><span lang="DE">Khan BF, Harissi-Dagher M, Khan DM, Dohlman CH,</span> Advances in Boston keratoprosthesis: enhancing retention and prevention of infection and inflammation, <i>Int Ophthalmol Clin, </i>2007;47(2):61–71.</span>
</li>
<li id="cite_note-:13-23"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:13_23-0">23.0</a></sup> <sup><a href="#cite_ref-:13_23-1">23.1</a></sup></span> <span class="reference-text">Baum J, Chaturvedi N, Netland PA,
Dreyer EB. Assessment of intraocular pressure by palpation. <i>Am J Ophthalmol </i>1995; 119:650 – 651. </span>
</li>
<li id="cite_note-24"><span class="mw-cite-backlink"><a href="#cite_ref-24">↑</a></span> <span class="reference-text">Birnbach CD, Leen MM. Digital palpation of intraocular pressure. <i>Ophthalmic Surg Lasers </i>1998; 29:754 –757. </span>
</li>
<li id="cite_note-25"><span class="mw-cite-backlink"><a href="#cite_ref-25">↑</a></span> <span class="reference-text">Rubinfeld RS, Cohen EJ, Laibson PR, et al. The accuracy of finger tension for estimating intraocular pressure after penetrating keratoplasty. <i>Ophthalmic Surg Lasers</i> 1998; 29:213–215. </span>
</li>
<li id="cite_note-26"><span class="mw-cite-backlink"><a href="#cite_ref-26">↑</a></span> <span class="reference-text">Kuo, DS et al. Correlation of Serial Scleral and Corneal Pneumatonometry. <i>Ophthalmology. </i>2015;122: 1771-1776.</span>
</li>
<li id="cite_note-27"><span class="mw-cite-backlink"><a href="#cite_ref-27">↑</a></span> <span class="reference-text">Kapamajian M, et al. Correlation Between Corneal and Scleral Pneumatonometry: An Alternative Method for Intraocular Pressure Measurement. <i>Am J Ophthalmol</i>. 2013; 156:902-906.</span>
</li>
<li id="cite_note-28"><span class="mw-cite-backlink"><a href="#cite_ref-28">↑</a></span> <span class="reference-text">Estrovich I, et al. Schiotz Tonometry Accurately Measures Intraocular Pressure in Boston Type 1 Keratoprosthesis Eyes. <i>Cornea. </i>2015;34:682-685.</span>
</li>
<li id="cite_note-29"><span class="mw-cite-backlink"><a href="#cite_ref-29">↑</a></span> <span class="reference-text">Williamson S, Cortina M. Boston type 1 keratoprosthesis from patient selection through postoperative management: a review for the keratoprosthetic surgeon. <i>Clin Ophthalmol</i>. 2016;10:437-443.</span>
</li>
<li id="cite_note-30"><span class="mw-cite-backlink"><a href="#cite_ref-30">↑</a></span> <span class="reference-text">Sayegh RR, Avena Diaz L, Vargas-Martin F, et al. Optical functional properties of the Boston Keratoprosthesis.<i> Invest Ophthalmol Vis Sci</i> 2010; 51:857–863&#160; &#160;&#160;</span>
</li>
<li id="cite_note-31"><span class="mw-cite-backlink"><a href="#cite_ref-31">↑</a></span> <span class="reference-text">Geoffrion D, Hassanaly SI, Marchand M, Daoud R, Agoumi Y, Harissi-Dagher M. Assessment of the Role and Timing of Glaucoma Surgery in Boston Keratoprosthesis Type 1 Patients. Am J Ophthalmol. 2021 Sep 17;235:249-257. doi: 10.1016/j.ajo.2021.09.005. Epub ahead of print. PMID: 34543660.</span>
</li>
<li id="cite_note-32"><span class="mw-cite-backlink"><a href="#cite_ref-32">↑</a></span> <span class="reference-text">Lenis TL, Chiu SY, Law SK, Yu F, Aldave AJ. Safety of Concurrent Boston Type I Keratoprosthesis and Glaucoma Drainage Device Implantation. <i>Ophthalmology</i>. 2016; 1-8.&#160; &#160;&#160;</span>
</li>
<li id="cite_note-33"><span class="mw-cite-backlink"><a href="#cite_ref-33">↑</a></span> <span class="reference-text">Dohlman CH, Grosskreutz CL, Chen TC, et al. Shunts to divert aqueous humor to distant epithelialized cavities after keratoprosthesis surgery.<i><span lang="FR"> J Glaucoma</span></i> 2010; 19:111 – 115. </span>
</li>
<li id="cite_note-34"><span class="mw-cite-backlink"><a href="#cite_ref-34">↑</a></span> <span class="reference-text">Kumar RS, Tan DT, Por YM, et al. Glaucoma management in patients with osteo-odonto-keratoprosthesis (OOKP): the Singapore OOKP Study. <i><span lang="FR">J Glaucoma </span></i>2009; 18:354–360&#160; &#160;&#160;</span>
</li>
<li id="cite_note-35"><span class="mw-cite-backlink"><a href="#cite_ref-35">↑</a></span> <span class="reference-text">Akpek EK, Harissi-Dagher M, Petrarca R, et al. Outcomes of Boston kera- toprosthesis in aniridia: a retrospective multi center study. <i>Am J Ophthalmol</i> 2007; 144:227 – 231.</span>
</li>
<li id="cite_note-36"><span class="mw-cite-backlink"><a href="#cite_ref-36">↑</a></span> <span class="reference-text">Tan DT, Tay AB, Theng JT, et al. Keratoprosthesis surgery for end-stage corneal blindness in Asian eyes. <i>Ophthalmology </i>2008; 115:503–510; e503. </span>
</li>
<li id="cite_note-37"><span class="mw-cite-backlink"><a href="#cite_ref-37">↑</a></span> <span class="reference-text">Semchyshyn TM, Tsai JC, Joos KM. Supplemental transscleral diode laser cyclophotocoagulation after aqueous shunt placement in refractory glaucoma. <i>Ophthalmology</i>. 2002;109: 1078–1084.</span>
</li>
<li id="cite_note-38"><span class="mw-cite-backlink"><a href="#cite_ref-38">↑</a></span> <span class="reference-text">Xu C, Chen TC, Chodosh J, Eliott D, Mukai S, Shen LQ, Vavvas DG, Young LH, Lin MM. Endoscopic Cyclophotocoagulation in Boston Keratoprosthesis Type II. Ophthalmol Glaucoma. 2021 Jul 12:S2589-4196(21)00170-8. doi: 10.1016/j.ogla.2021.07.002. Epub ahead of print. PMID: 34265498.</span>
</li>
</ol></div>
<!-- 
NewPP limit report
Cached time: 20230306035154
Cache expiry: 86400
Dynamic content: false
Complications: [my_variables_no_cache]
[SMW] In‐text annotation parser time: 0 seconds
CPU time usage: 0.266 seconds
Real time usage: 1.852 seconds
Preprocessor visited node count: 1224/1000000
Post‐expand include size: 6645/2097152 bytes
Template argument size: 1578/2097152 bytes
Highest expansion depth: 11/40
Expensive parser function count: 0/100
Unstrip recursion depth: 0/20
Unstrip post‐expand size: 9081/5000000 bytes
-->
<!--
Transclusion expansion time report (%,ms,calls,template)
100.00%  641.257      1 Template:Article
100.00%  641.257      1 -total
 82.01%  525.878      4 Template:Infobox_section
 37.89%  242.948      8 Template:UserLookup
  0.74%    4.721      1 Template:Review_expired
  0.24%    1.548      1 Template:Get_active_contest
  0.14%    0.917      1 Template:Infobox_end
  0.14%    0.888      1 Template:Infobox_begin
-->
</div></div><div class="printfooter">
Retrieved from "<a dir="ltr" href="https://eyewiki.org/w/index.php?title=Management_of_Glaucoma_in_Eyes_with_Boston_Keratoprosthesis&amp;oldid=84960">https://eyewiki.org/w/index.php?title=Management_of_Glaucoma_in_Eyes_with_Boston_Keratoprosthesis&amp;oldid=84960</a>"</div>

						<!-- end body text -->
						<!-- data blocks which should go somewhere after the body text, but not before the catlinks block-->
						<div id='mw-data-after-content'>
	<div class="mw-cookiewarning-container"><div class="mw-cookiewarning-text"><span>The Academy uses cookies to analyze performance and provide relevant personalized content to users of our website.</span></div><form method="POST"><div class='oo-ui-layout oo-ui-horizontalLayout'><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-progressive oo-ui-buttonWidget'><a role='button' tabindex='0' aria-disabled='false' href='https://www.aao.org/privacy-policy' rel='nofollow' class='oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-progressive'></span><span class='oo-ui-labelElement-label'>Learn more</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-progressive'></span></a></span><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-inputWidget oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-primary oo-ui-flaggedElement-progressive oo-ui-buttonInputWidget'><button type='submit' tabindex='0' aria-disabled='false' name='disablecookiewarning' value='OK' class='oo-ui-inputWidget-input oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-invert'></span><span class='oo-ui-labelElement-label'>Accept</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-invert'></span></button></span></div></form></div>
</div>

					</div>
					<!-- category links -->
					<div id="catlinks" class="catlinks" data-mw="interface"><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/Special:Categories" title="Special:Categories">Categories</a>: <ul><li><a href="/Category:Articles" title="Category:Articles">Articles</a></li><li><a href="/Category:Cornea/External_Disease" title="Category:Cornea/External Disease">Cornea/External Disease</a></li><li><a href="/Category:Glaucoma" title="Category:Glaucoma">Glaucoma</a></li></ul></div></div>
				</div>
			</div>
		</div>
	</div>
	<div class="mb-2 mt-4 footer container">
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar not-collapsible small mb-2" role="navigation" id="mw-navigation-hbpzyw6z7q">
					<div class="navbar-nav">
					<!-- toolbox -->
					<div id="t-whatlinkshere" class="nav-item"><a href="/Special:WhatLinksHere/Management_of_Glaucoma_in_Eyes_with_Boston_Keratoprosthesis" title="A list of all wiki pages that link here [j]" accesskey="j" class="nav-link t-whatlinkshere">What links here</a></div>
					<div id="t-recentchangeslinked" class="nav-item"><a href="/Special:RecentChangesLinked/Management_of_Glaucoma_in_Eyes_with_Boston_Keratoprosthesis" rel="nofollow" title="Recent changes in pages linked from this page [k]" accesskey="k" class="nav-link t-recentchangeslinked">Related changes</a></div>
					<div id="t-specialpages" class="nav-item"><a href="/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q" class="nav-link t-specialpages">Special pages</a></div>
					<div id="t-print" class="nav-item"><a href="javascript:print();" rel="alternate" title="Printable version of this page [p]" accesskey="p" class="nav-link t-print">Printable version</a></div>
					<div id="t-permalink" class="nav-item"><a href="/w/index.php?title=Management_of_Glaucoma_in_Eyes_with_Boston_Keratoprosthesis&amp;oldid=84960" title="Permanent link to this revision of the page" class="nav-link t-permalink">Permanent link</a></div>
					<div id="t-info" class="nav-item"><a href="/w/index.php?title=Management_of_Glaucoma_in_Eyes_with_Boston_Keratoprosthesis&amp;action=info" title="More information about this page" class="nav-link t-info">Page information</a></div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- footer links -->
				<div id="footer-info" class="footer-info">
					<!-- info -->
					<div> This page was last edited on September 12, 2022, at 06:26.</div>
					<div>This page has been accessed 20,207 times.</div>
				</div>
				<!-- places -->
				<div id="footer-places" class="footer-places">
					<div><a href="/EyeWiki:Privacy_policy" title="EyeWiki:Privacy policy">Privacy policy</a></div>
					<div><a href="/EyeWiki:About" title="EyeWiki:About">About EyeWiki</a></div>
					<div><a href="/EyeWiki:General_disclaimer" title="EyeWiki:General disclaimer">Disclaimers</a></div>
				</div>
			</div>
			<div class="col">
				<!-- footer icons -->
				<div id="footer-icons" class="justify-content-end footer-icons">
					<!-- poweredby -->
					<div><a href="https://www.mediawiki.org/"><img src="/w/resources/assets/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="/w/resources/assets/poweredby_mediawiki_132x47.png 1.5x, /w/resources/assets/poweredby_mediawiki_176x62.png 2x" width="88" height="31" loading="lazy"/></a></div>
					<div><a href="https://www.semantic-mediawiki.org/wiki/Semantic_MediaWiki"><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAFgAAAAfCAMAAABUFvrSAAACJVBMVEXe3t62trbLy8vGxsbAwMDX19e6urqsrKxHcEzQ0NC2tratra2oqKixsbHd3eDFxcXe3t7U1NTa2trX19fQ0NDV1dWNjY2dnZ2UlJSUlJTS0tKUlJSWlpbR0dGenp79/f38/Pz+/v7t7e3v7+/u7u7s7Oz19fX29vb6+vr7+/vz8/Pz8/P4+fnw8PD39/gWTq/09PX6+vktX7b/sg8XT7F6mc/f5OwhVrNvkMthhsfT2+j7rQ/M1eZqjcmFotPs7e9Cb722xuFResK/zOObstnu7/Grvd3M1+mNqNY6aLoaUbEaUbZWfsTk6fE2Zrnp7O8bTq0kWLQuYcpcg8Xh5/Byk83a4eukud1/nM+6yeQkWcGwwuDxnRQyYrigttvI0+gpW7XGyttLdsBni8geVLo0Z9XlkCPb4u+QqtcfVLLo7PNHcr73phFGX6HsmBnpkxg6bNwnXcbX3er19vnr7/SVrdhuhLl+j70vVqY6Xqv0oxJVcbQhV76DjKTz9ffQ2evE0OZAbbzu7/PS1uFufrDnrGgpSZjy8/SQnMFddrKuekXSiCsgTKRaaZHejy9yang3VptNaqspWbnmliy3j2/m6OzT3e7x8fL4+v3p6uwaN2re0cifqLiLiZWYhYGYb0xXYn+5g0xwiMKYpc2BcHZmW2srRXpGWIhecKfilz4+WID2+PyosMywqbGqss1aVnLZq33p1sGklZqrp7dkfr7CpY9yg59Ud6QZAAAAH3RSTlPfBN/f39/f2wDf39vV3/7N2rrEz5D5c8ONuHaPuXXDImoxqwAABO1JREFUSMe1kQdz01gQgBXaBS4w9OtHwMFSdPKTUNxkW+61xN2Je4tLHJNOGukkAUINJTzaUIbO9fr7TpLtS44DZiC5b6Sn3dW+TysJaWz4cv9eZFPZu/+bhkakYR88WqP59u3vjxzdDCT7GpCD4qNH3sEGzOhB5MCR/4PmA8j25uZ33t0A23lxff5hZTIzOrz2Ph8qK936l7i1tT7hk8DAoHNsbeLWKjPdQcZ+qvX9tHMNXca1XBDXHtL6x2Bh0HWtuXUo8oTgC1gVpcdsdpew92PUYtjwzFq+E9mJYfXxx1x5l2/l5Vhy0DW6TuyQCZcR2hnswXJM0h+203471u5WKMIE5mDpspIIO8sZTMZiIbczY6+JCaI+/sJZ38qjP28+nQjkx/mcqGJ26rW3iKg/fYphCL1jNk5WbqXI0nBnu00RJ2j9bNRp6MmFS0SYIXLuUlQ5w22qizHr5MTyy2u/3XxVvHHlwtWVa/xTCQIIlEaMzrgswzA5P9BrAciYASqNoiNdjL8b0GYAHN3AGAEgzPSQc9UtYCeyBQAMO2G9PhhzXfp9qdifSCT6Lj788QQnrvWEuNPI2um0LW0D+m4A6E4AnIZOeq7ksQuJvi6eUXRW+8EWXsxNPhkYGJiSXr7Rd1qtVp9MXHkgIurzAkdFxjrj7cmKbN4K5v8RGxT2sJMTpwBflNHhUJgBdoUylzy3TuwIDBRi0hf9p9VtbW3qk30X7q2Je1IybZq7mLVWFKTSADXPoqi9AzVorda0kKTS6KkRbSgaR1GT1h5CObYiW1GU27yc5z6F9Fn/yTYedeLi9AIA6AbgxGIxAMPZcZeUHH9cFavVfY97FaNA/DbazRZVV89/61at2BTlg1JXiFtrYoBmRyd7p6/UP0XxaSDmy4pt0jmuh8qx6wQ2MmRz18TaJCUWO9xisUVhMMsoZZDiGHLLuXUbso2iatP/1HvhYu3n3bh6Pe/LUjZSj1NUJ8lSlNwahRRlMRjmyFDICikVn8+SacomdbZTVj+0mQSxweS1WqpiHK/Ncubs858f9idOJ/qKS1cv+RbFuIbMmHEvTbO4QeF25CxyD62nSbmJ1MUzRrpiwR0RPBJMpnCGxWVGXBn8TkarNGQHjuPrxOeWY4GY9FmxWHy19Gvv+ayYF6f8oYi7i8U93bjFkYokvbhWEFu8Og2ZxrUe3NMpc3vLhqqYpVV4XbwDQkpgoVwYKOR9N5d+eXB5vJevQA0pD7oVqi4WOj16vX6EYSA08WKvyeOZJw1cQ6rsnXOa/RYoM0Kls0zLuVoHhHAHL8YFXkwVCoE8uXhvMVCY8mW5Ci8eKkcgJ9azOl0UajNDFiUpj5JeloEqTgwd/iCUJP0sFMSejkpO96b4zl1fPuYiyd6Vs4GBmHSsJoYmLy/WeBTlis5rlJYrgjhe1s+XOXGEtHJOMl4VB2EHLauKdyG7JBLIc//uslRKkhOrcGJqyiU9z5UkOpVOwiGXSyQizRAfqlRc7Y5KJFnV6FReiWSV7xAWeQd/SOSq6qY18eVHq4vjlyazEJ73ScmJPVxJVKdF9MFwYpFIEL+ehvDOcSH8YXRsAa4XfwS7kd0tLfw7Sp7fl7xJywbYjTTVotfTb+849lEcb0K+2lMN/5o+tons+Rxp+PrQ8U3n0BcNSGPj4W+bPuX5ZLNo+uxwY+PfoLJHX1KXgyMAAAAASUVORK5CYII=" alt="Powered by Semantic MediaWiki" class="smw-footer" width="88" height="31" loading="lazy"/></a></div>
				</div>
			</div>
		</div>
	</div>
<script src="https://www.googletagmanager.com/gtag/js?id=UA-64665049-1" async=""></script><script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config', 'UA-64665049-1', {});
</script>

<script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgPageParseReport":{"smw":{"limitreport-intext-parsertime":0},"limitreport":{"cputime":"0.266","walltime":"1.852","ppvisitednodes":{"value":1224,"limit":1000000},"postexpandincludesize":{"value":6645,"limit":2097152},"templateargumentsize":{"value":1578,"limit":2097152},"expansiondepth":{"value":11,"limit":40},"expensivefunctioncount":{"value":0,"limit":100},"unstrip-depth":{"value":0,"limit":20},"unstrip-size":{"value":9081,"limit":5000000},"timingprofile":["100.00%  641.257      1 Template:Article","100.00%  641.257      1 -total"," 82.01%  525.878      4 Template:Infobox_section"," 37.89%  242.948      8 Template:UserLookup","  0.74%    4.721      1 Template:Review_expired","  0.24%    1.548      1 Template:Get_active_contest","  0.14%    0.917      1 Template:Infobox_end","  0.14%    0.888      1 Template:Infobox_begin"]},"cachereport":{"timestamp":"20230306035154","ttl":86400,"transientcontent":false}}});mw.config.set({"wgBackendResponseTime":4477});});</script></body>
</html>